Research programme: T cell therapeutics - Celgene/Juno Therapeutics

Drug Profile

Research programme: T cell therapeutics - Celgene/Juno Therapeutics

Alternative Names: Autoimmune disorder therapeutics - Celgene/Juno; Cancer therapeutics - Celgene/Juno; CAR T cell products - Celgene/Juno; Chimeric antigen receptor T lymphocytes - Celgene/Juno; TCR T cell products - Celgene/Juno

Latest Information Update: 16 Jul 2015

Price : $50

At a glance

  • Originator Celgene Corporation; Juno Therapeutics
  • Class CAR-T cell therapies; Immunotherapies
  • Mechanism of Action Immunomodulators; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 29 Jun 2015 Celgene and Juno agree to co-develop and co-promote immunotherapies in countries worldwide for Cancer and Autoimmune disorders
  • 29 Jun 2015 Early research in Autoimmune disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top